All the news Showing 10 of 676 articles from: TherapiesGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Fair Pricing Coalition Recognizes Merck’s Lower Price for Curative Hepatitis C Treatment, Calls for Manufacturers to Reduce Excessive Prices and Increase Patient Assistance Fair Pricing Coalition / 08 February 2016 Olysio/Sovaldi yield high SVR post-liver transplant Healio / 08 February 2016 Daclatasvir approved for use in HIV/HCV co-infection, decompensated cirrhosis and post-transplant in the EU Keith Alcorn / 03 February 2016 The hepatitis C direct-acting antiviral daclatasvir (Daklinza) has received European Union marketing approval for use in three new populations of people with genotype 1, 3 or 4 hepatitis C infection. The NS5A inhibitor ... Merck Throws a Wrench in Drug Pricing Bloomberg / 01 February 2016 New Merck combination pill Zepatier approved for hepatitis C treatment in the United States Keith Alcorn / 01 February 2016 Merck has received a US license for its direct-acting antiviral combination of grazoprevir and elbasvir, to be marketed as Zepatier. The combination of grazoprevir (an HCV protease inhibitor) and elbasvir (an NS5A inhibitor) ... European Commission Approves Daklinza (daclatasvir) for the Treatment of Genotype 1, 3 and 4 Chronic Hepatitis C Patients with HIV Coinfection, Advanced Cirrhosis and Post-liver Transplant Recurrence of HCV Bristol-Myers Squibb press release / 01 February 2016 Zepatier for hepatitis C approved in Canada CATIE / 01 February 2016 Merck Receives FDA Approval of ZEPATIER™ (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Genotype 1 or 4 Infection in Adults Merck press release / 29 January 2016 The Medicines Patent Pool Signs First Sub-licences for Hepatitis C Medicine Daclatasvir Medicines Patent Pool / 20 January 2016 Three-drug regimens taken for 8 weeks demonstrate high hepatitis C cure rate Liz Highleyman / 13 January 2016 An interferon-free regimen containing Merck's grazoprevir, the NS5A inhibitors elbasvir or MK8404, and the experimental nucleotide polymerase inhibitor MK-3682, taken for 8 weeks, cured more than 90% of hepatitis C ... ← Prev1...910111213...68Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Transmission and prevention Diagnosis and monitoring Disease course and symptoms HCV and coinfections Living with HCV Treatment issues Side effects Therapies Liver transplants Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Noticeboard Email bulletins News feeds